Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2157-2164

  Chung, Wen Hung ^a,b   Chang, Wan Chun ^c   Stocker, Sophie L ^d,e   Juo, Chiun Gung ^f   Graham, Garry G ^d,e   Lee, Ming Han H ^d,e   Williams, Kenneth M ^d,e   Tian, Ya Chung ^b,f   Juan, Kuo Chang ^b,f   Wu, Yeong Jian Jan ^a,b   Yang, Chih Hsun ^a,b   Chang, Chee Jen ^a,f   Lin, Yu Jr ^a,f   Day, Richard O ^d,e   Hung, Shuen Iu ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; GRANULYSIN; HLA B ANTIGEN; OXIPURINOL; GNLY PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRESS SYNDROME; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HAN CHINESE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEVERE CUTANEOUS ADVERSE REACTION; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TAIWAN; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; ADOLESCENT; BLOOD; DRUG ERUPTIONS; EPIDEMIOLOGY; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; RENAL INSUFFICIENCY; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DRUG ERUPTIONS; FEMALE; FOLLOW-UP STUDIES; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; OXYPURINOL; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 84952990733     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205577     Document Type: Article

References (42)

1. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
2. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55.
3. Nuki G. An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout. Curr Opin Rheumatol 2014;26:152-61.
4. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
5. Stocker SL, Graham GG, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011;38:904-10.
6. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
7. Kuzell WC, Glover RP, Gibbs JO, et al. Effect of Sulfinpyrazone on Serum Uric Acid in Gout. A Long-Term Study. Geriatrics 1964;19:894-909.
8. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337-43.
9. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-16.
10. Hung SI, Chung WH, Liou LB, et al. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9.
11. Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012;8:610-21.
12. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
13. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013;13:60-9.
14. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B∗5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-9.
15. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007;46:623-44.
16. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013;43:1246-55.
17. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
18. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-50.
19. Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009;151:514-5.
20. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979;1:365-74.
21. Perez-Ruiz F, Hernando I, Villar I, et al. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005;11:129-33.
22. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013;36:953-80.
23. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36.
24. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
25. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
26. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.
27. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
29. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8.
30. Stocker SL, Williams KM, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008;47:111-18.
31. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
32. Paisansinsup T, Breitenstein MK, Schousboe JT. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. J Clin Rheumatol 2013;19:180-6.
33. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med 1974;134:553-8.
34. Simmonds HA. Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol. Clin Chim Acta 1969;23:353-64.
35. Reiter S, Loffler W, Grobner W, et al. Allopurinol-1-riboside formation and HGPRT-deficiency. Adv Exp Med Biol 1986;195(Pt A):447-51.
36. Stamp LK, Barclay ML, O'Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 2011;90:392-8.
37. Genin E, Schumacher M, Roujeau JC, et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis 2011;6:52.
38. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.
39. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-22.
40. Dainichi T, Uchi H, Moroi Y, et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007;215:86-8.
41. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55.
42. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9.